"The U.S. Food and Drug Administration today expanded the approved use of the CoreValve System to treat certain patients who have previously had a tissue aortic valve replacement and are in need of a second one.
This first-of-its-kind use is"...
NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) possesses predominantly α-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic, by constricting ophthalmic blood vessels and the radial muscle of the iris.
The ophthalmologic usefulness of NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) hydrochloride is due to its rapid effect and moderately prolonged action, as well as to the fact that it produces no compensatory vasodilatation.
The action of different concentrations of ophthalmic solutions of NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) hydrochloride is shown in the following table:
|Strength of solution (%)||Mydriasis||Paralysis of accomodation|
|Maximal (minutes)||Recovery time (hours)|
Although rare, systemic absorption of sufficient quantities of phenylephrine may lead to systemic α-adrenergic effects, such as rise in blood pressure which may be accompanied by a reflex atropine-sensitive bradycardia.
Last reviewed on RxList: 5/6/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Neo-Synephrine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.